Acute myeloid leukemia (AML) encompasses a group of very heterogeneous diseases both in terms of presentation and outcome. Thus far, cytogenetic abnormalities are widely recognized as the most important prognostic factors and serve as basis for treatment decision algorithms. The AML subgroup without cytogenetic abnormalities accounts for around 40-50% of all AML cases.
1 In this subgroup, two particular gene alterations have been shown to confer prognostic relevance. On one hand, internal tandem duplications of the fms-related tyrosine kinase 3 gene (FLT3-ITD þ ) have been associated with poor outcome. On the other hand, mutations in the nucleophosmin gene (NPM1 þ ) have been associated with a favorable outcome (reviewed in Bacher et al.
2 ). Therefore, assessment of these two factors allowed for identifying a particularly favorable subgroup of patients. Indeed, AML patients presenting with a mutation for NPM1 without concomitant FLT3-ITD can have a better outcome compared with patients presenting with other combinations. Moreover, a recent study from the GermanAustrian AML Study Group 1 proposed to classify these patients in the favorable risk leukemia group similar to the core-binding factor AML subgroup, in which allogeneic stem cell transplantation in first complete remission (CR) is not recommended anymore. However, all the above-mentioned studies have considered NPM1/FLT3-ITD status at diagnosis and to the best of our knowledge no series has focused on the effect of the NPM1/FLT3-ITD status at the time of disease relapse, especially in terms of response to salvage therapy and overall outcome. We have previously shown that salvage chemotherapy including gemtuzumab ozogamicin (GO) is a valid option for the treatment of relapsed/refractory CD33 þ AML patients.
3 With this background, the aim of this report was to investigate the influence of the NPM1/FLT3-ITD status on outcome in relapsed/ refractory AML patients with normal karyotype who received a salvage regimen using GO as monotherapy or in combination with other agents.
For this purpose, we analyzed the outcome of 57 AML patients with normal karyotype treated in four institutions (Nantes, Marseille, Bordeaux and Angers) in France, between 2001 and 2009. Patients received GO as monotherapy or in combination with other chemotherapeutic agents at time of relapse (n ¼ 36) or in the setting of refractory disease (n ¼ 21). There were 26 men and 31 women with a median age of 52 (range, 20-70) years at time of leukemia diagnosis. The FrenchAmerican-British distribution included 2, 13, 15, 11, 12 and 1 AML cases from the M0, M1, M2, M4, M5 and M6 subgroups, respectively. Three cases were considered as unclassified. In addition, five patients had secondary AML. All patients were CD33 þ with a median CD33 expression level of 98%. As salvage treatment, 46 patients received the MIDAM regimen (GO: 9 mg/m 2 at day 4 þ cytarabine 1 g/m 2 every 12 h for days 1-5 þ mitoxantrone 12 mg/m 2 per day for days 1-3). 3 In two patients receiving the MIDAM regimen, mitoxantrone was omitted to avoid cardiac toxicity. Four patients received GO as monotherapy at 9 mg/m 2 (n ¼ 3) or at 6 mg/m 2 (n ¼ 1). The five remaining patients received GO 3-9 mg/m 2 combined with other chemotherapeutic agents (cytarabine þ VP16 þ GO, n ¼ 2; cytarabine þ idarubicin þ GO, n ¼ 2; cytarabine þ amsacrine þ GO, n ¼ 1). After salvage therapy, 25 patients could proceed and receive consolidation with an allogeneic stem cell transplant.
In this series, all patients could be screened in the blood or bone marrow for mutations in the FLT3 gene (ITD mutations) and in the NPM1 gene at diagnosis as previously described.
4,5 Same proportion of refractory patients was observed in the favorable NPM1 þ /FLT3-ITDÀ group compared with the others patients (36%, n ¼ 5/14 vs 37%, n ¼ 16/43). Probability of overall survival (OS) was calculated using the Kaplan-Meier estimates. The logrank test was used for univariate comparisons.
In this series, with a median follow-up of 23.3 (range, 2.3-94.5) months for surviving patients, OS was 46.5% (95% CI, 33.6-59.9) at 2 years. CR, relapse and death rates according to disease and NPM1/FLT3-ITD status, and causes of death are detailed in Table 1 . The CR rate was higher in patients with NPM1 þ /FLT3-ITDÀ status (85 vs 60% for all others, P ¼ 0.16) whereas the relapse rate was lower in this subgroup (33 vs 42% for all others, P ¼ 0.87) but the differences were not significant. Conversely, the death rate was significantly lower in patients with NPM1 þ /FLT3-ITDÀ (28 vs 65%, P ¼ 0.02). As a consequence, OS was significantly higher in this subgroup, in comparison to patients from the other subgroups (P ¼ 0.026; Figure 1a ).
To the best of our knowledge, this is likely among the first largest series that assessed the role of the NPM1/FLT3-ITD status as prognostic factor for cytogenetically normal AML patients receiving salvage therapy in the refractory or relapsed setting. Recently, Meloni et al.
6 reported a single case describing the outcome of a 19-year-old woman who relapsed 5 years after diagnosis of AML. Of note, this patient presented with two different karyotypes (del(13;14) and t(4) then normal karyotype, respectively) and NPM1/FLT3-ITD status (NPM1 þ /FLT3-ITD þ and NPM1 þ /FLT3À, respectively) between diagnosis and relapse. The patient received a combination of cytarabine, idarubicin and GO as salvage therapy and could achieve a second CR, suggesting a favorable effect for the NPM1 þ /FLT3À status at relapse. 6 Results from the current analysis suggest the favorable effect of an NPM1 þ /FLT3-ITDÀ status is still retained at relapse or when receiving treatment for a refractory disease. However, one should bear in mind, that all patients from our series received GO, which was not able to improve the dismal prognosis of patients without the favorable mutation status (Figure 1b) . Others strategies including, for example, an anti-FLT3 inhibitor such as sorafenib may prove more usefulness. 7 One caveat of our study is that we have studied the molecular status of the patients only at diagnosis, and not at time of relapse immediately before salvage therapy. However, this is unlikely to be a major concern as NPM1 mutation status is shown to be very stable in the course of the disease (relapse or refractory disease)
suggesting that it could be used as a marker for monitoring of minimal residual disease. 8 However, FLT3-ITD status has shown more variability, but the overall de novo acquisition of a FLT3-ITD mutation was reported to be o5% in the favorable NPM1 þ /FLT3-ITDÀ subgroup. 8 In all, and although this needs to be confirmed in a prospective setting refractory/relapsed AML patients with a normal caryotype and a NPM1 þ /FLT3-ITDÀ are likely to remain in a 'favorable prognosis' category when receiving salvage therapy. Such information is of major interest for patients counseling and for the design of salvage therapy approaches.
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The additional sex comb-like 1 (ASXL1) gene, located in the chromosomal region 20q11, belongs to a family of three identified members that encode poorly characterized proteins regulating chromatin remodeling. The ASXL proteins contain a C-terminal PHD (Plant Homeo Domain) finger and belong to the polycomb and trithorax complexes, which regulate the genetic program of stem cells. We have recently shown that ASXL1 is mutated in roughly 10% of myelodysplastic syndromes, 2 10% of myeloproliferative neoplasms 3 and 40% of chronic myelomonocytic leukemias.
2 Using array comparative genomic hybridization (aCGH), we also observed a deletion of the ASXL1 locus in a myelodysplastic syndrome case.
2 These observations suggest that ASXL1 is a tumor suppressor whose haploinsufficiency has a role in myeloid diseases. The predicted truncated ASXL1 protein would lack its PHD finger, which could prevent it from binding methylated histone lysines and interacting with chromatin modifiers, thus enhancing self-renewal in hematopoietic progenitors. 4 To determine whether ASXL1 is involved in AML, we used DNA sequencing and aCGH to search for mutations and deletions of the gene in 46 cases of AML with normal karyotype and 17 cases with trisomy 8 (n ¼ 14), 9q deletion (HD-0632), trisomy 11 (HD-0304) or 20q11-13 deletion (HD-0381) as a sole karyotypic abnormality. The 63 AMLs were 46 primary cases and 17 transformations of a previous myeloid disease (of which seven have been previously reported 2 ). We did not include therapy-related AMLs. All patients signed an informed consent and the study was approved by our institutional review board. We have previously described primers and conditions for ASXL1 DNA amplification and sequencing.
2 Fifty cases were also studied by aCGH with high-density oligonucleotide arrays (Hu-244A, Agilent Technologies, Massy, France), as previously described. 5 We also searched for mutations in CEBPA (exons 1-8), FLT3 (internal tandem duplicationsFITDsFand point mutation in exon 20-encoded kinase domainFTKD), JAK2 (exon 14), K and NRAS (exons 1 and 2), and NPM1 (exon 12), as well as in CXXC5, FES and TAL1, three genes found altered by gain or loss in aCGH analysis.
In all, 41 out of the 50 cases studied by aCGH did not show any copy number aberration (isolated trisomy 8 was not taken into account). The deletion of chromosomal region 20q11-13 (HD-0381), which was visible on the karyotype, involved ASXL1 (Table 1) . We found heterozygous nonsense or frameshift mutations of ASXL1 in 11 out of the 63 cases (B17.5%) ( Table 1) . We also found several cases of substitution, which we did not take into account because they may represent polymorphisms. Thus, in total, 12 cases out of 63 showed ASXL1 alteration (19%). In two cases, we sequenced ASXL1 in DNA extracted from buccal smears of the patient with ASXL1 mutation; ASXL1 was not mutated, showing that the mutation was acquired.
In agreement with what is known for AML with normal karyotype, 5 almost half of the cases (28 out of 63, 44%) showed exon 12 NPM1 mutations. NPM1 mutations were mutually exclusive with ASXL1 alterations: none of the 28 NPM1-mutated cases showed ASXL1 mutation or deletion, whereas 12 out of the 35 (34%) non-NPM1-mutated cases were mutated or deleted for ASXL1 (P ¼ 0.0018). Three ASXL1 missense mutations, for which we do not know whether they are acquired or not, were also detected in cases without NPM1 mutations. FLT3 mutations (n ¼ 6) and ITD (n ¼ 14) were found in 19 cases (30%) and were not observed with ASXL1 mutations except in one case (HD-0282). Three cases were mutated in either K or NRAS, and one case in JAK2. Data on CEBPA, available for 11 cases, revealed no mutation. Finally, we did not find any mutation of CXXC5, FES and TAL1 genes.
Several tumor suppressors (for example, RB1, p53, RUNX1, 5 TET2, 2,3,6-13 ASXL1 2,3 ) are inactivated in various types of myeloid diseases. With respect to ASXL family members, deletions of ASXL1, ASXL2 and ASXL3 have been reported.
2,11
Mutations of ASXL1 are found in myelodysplastic syndromes 2 and myeloproliferative neoplasms, 3 suggesting that additional alterations are responsible for acute transformation; as the AMLs studied by us were not associated with translocations, these alterations are not well-known fusion genes but other mutations. They are not mutations of NPM1 as these were mutually exclusive with ASXL1 mutations. This could suggest that the NPM1 and ASXL1 mutations are epistatic. We could speculate that ASXL1 and NPM1 have distinct functions but act at some moment on the same cellular control. One such control could be the regulation of 9p INK4A-ARF-INK4B loci, which constitute an important node for the regulation of senescence and self-renewal and are regulated by polycomb complexes as well as NPM1, a histone chaperone.
1 ASXL1 could have a role in this regulation through its interaction with polycomb proteins.
